Noticias de ASRT_US
Noticias del mercado
Últimas noticias sobre ASRT_US — 212 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Zydus adquirirá Assertio, con sede en EE. UU., en una oferta pública de adquisición totalmente en efectivo
Zydus Lifesciences anunció la adquisición de Assertio por 166,4 millones de dólares, fortaleciendo su presencia en el mercado farmacéutico global.
Zydus Lifesciences adquirirá la empresa estadounidense Assertio por 166 millones de dólares, mejorando su cartera de oncología y su presencia en Estados Unidos.
Vea los estados de resultados trimestrales de las acciones ordinarias de Assertio Holdings, Inc. (ASRT). Vea los ingresos, los gastos y las ganancias o pérdidas del trimestre más reciente.
Zydus Worldwide DMCC to Acquire Entire Stake in Assertio Holdings for USD 166.4 Million
Assertio gets sweetened $153M buyout offer from Garda Therapeutics
Zydus to acquire US-based Assertio for $166.4 million
Zydus Lifesciences buys US-based Assertio Holdings for $166.4 million to boost oncology presence
Zydus Lifesciences to acquire Assertio for USD 166.4 mn
Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..
Zydus to acquire US cancer drug company Assertio for $166.4 million in all-cash deal
Zydus Lifesciences to Acquire U.S. Oncology Player Assertio in USD 166 Million Deal
Zydus to buy US drugmaker Assertio for $166 million to expand cancer treatment business
Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders
Zydus Worldwide DMCC agreed to acquire Assertio Holdings, Inc. for approximately $170 million.
Assertio (ASRT) moves 17.0% higher: Will this strength last?
Zydus to acquire US-based Assertio for ₹1,592 cr
Assertio Therapeutics to Be Acquired by Zydus Worldwide
Assertio Holdings to Be Acquired by Zydus Worldwide DMCC for $23.50 per Share in All-Cash Deal
Assertio to Be Acquired by Zydus for $23.50 Per Share in Tender Offer and Merger
Página 1 de 11
